



## **Ciliatech selected to showcase Intercil® Uveal Spacer, novel glaucoma surgical device, at Eyecelerator**

**Major event for advancing innovation in eye care gives Ciliatech first-time opportunity to show US ophthalmic audiences potential of treating open and narrow angle glaucoma in supraciliary space with single device**

**Chavanod (near Annecy), France, October 10, 2024** - Ciliatech, an innovative medtech company focusing on the treatment of glaucoma, today announces its selection to showcase Intercil® Uveal Spacer, its brand-new concept in surgical devices with capabilities of addressing both open and narrow forms of glaucoma, at [Eyecelerator](#), an event for advancing eye care innovation taking place in Chicago on October 17. This is the first time that Ciliatech will present its disruptive technology that works in an underused treatment pathway - the supraciliary space - to US audiences comprising ophthalmic experts, investors and industry executives.

Ciliatech will also present its three-year clinical follow-up data, the results from one of several clinical trials underway, as part of its preparations to obtain CE marking by Q1, 25 and launch a US study.

Ciliatech's participation represents a major opportunity for the company to reach the largest audience of commercially successful ophthalmic businesses looking to expand their portfolios, engage with venture capitalists and explore industry partnerships.

"Ciliatech is very proud to have been selected by Eyecelerator to present the Intercil Uveal Spacer and its clinical outcomes to a targeted ophthalmic audience across the Atlantic. They will see the substantial added value our glaucoma device brings to surgeons and patients, where a strong need remains for safer and more efficient solutions to treat glaucoma," said Olivier Benoit, president and CEO of Ciliatech. "Today, we have more than 100 patients enrolled in various trials, a reliable proven technology with solid IP and a device at the forefront of a new class for treatment, showing that opening the anterior chamber of the eye to treat glaucoma may be considered undesirable or even unnecessary. This concept eliminates many post-op complications currently endured by patients. Our implant is progressing towards market approval in Europe with a view to starting the registration process in the US."

### **Key features**

Eyecelerator provides companies with a valuable opportunity to showcase among a targeted ophthalmic audience that is primed to accelerate market introductions. Ciliatech is one of roughly a dozen ophthalmic equipment makers selected to pitch in the [Glaucoma/Digital Showcase](#) program; having demonstrated Intercil Uveal Spacer's efficacy and safety, and providing 36-month clinical follow-up data showing an impressive and sustained decrease in intraocular pressure (IOP) and reduction in medication dependence. The device's unique features, such as its improved safety, its potential to treat narrow angle glaucoma patients and the ability to position it anywhere around the eye, favored its selection.

Intercil's capacity to treat narrow angle glaucoma, which differentiates it from other implants, could potentially fill a considerable treatment gap in this patient category. Narrow angle glaucoma affects more than [17 million people](#) worldwide, with a far higher prevalence



in Asia. It is estimated that by 2050, the global population with Primary Angle Closure Glaucoma (PACG) will be 26.3 million, with 18.5 million in Asia. This represents a substantial market opportunity.

It is well established within scientific literature that the uveoscleral outflow pathway is [compromised with age and disease](#). Ciliatech's Intercil Uveal Spacer seeks to uniquely re-establish this natural outflow pathway without needing to enter the anterior chamber of the eye.

#### **Eyecelerator Glaucoma/Digital Showcase:**

- Presenter: Olivier Benoit, president and CEO of Ciliatech
- Thursday, October 17, at 1:17pm (CDT) - McCormick Place Convention Center, Chicago

#### **About Ciliatech**

Ciliatech is an innovative medtech company focusing on the treatment of glaucoma – a disease that affects 80 million people worldwide. Its Intercil® Uveal Spacer, a groundbreaking implant in the new 'Cilioscleral interpositioning Device' (CID) category, will be the first proprietary glaucoma device that treats both the open and narrow angle forms of the disease. Clinical trial follow-up of patients implanted with the device has now reached the three-year mark; demonstrating highly positive results in robust IOP-lowering coupled with a very high safety profile. Multiple clinical trials of the second-generation CID are in progress, whilst the company is actively pursuing regulatory approvals. CID's bespoke surgical implantation technique - facilitating external placement into the supraciliary space of the eye without ever entering the eye's anterior chamber - sets it apart from other glaucoma procedures.

Co-founded in 2017 by ophthalmic surgeon and inventor Dr. Philippe Sourdille, and Olivier Benoit, a veteran engineer and biotech entrepreneur, Ciliatech has to date raised €6m (\$6.5m) and is expanding its scientific, medical and commercial team. The company is located near Annecy, France.

[www.cilia.tech](http://www.cilia.tech)

Legal disclaimer: Ciliatech products are currently not available for sale pending regulatory approvals.

---

Media and analyst contact  
**Andrew Lloyd & Associates**  
Carol Leslie / Juliette Schmitt  
[carol@ala.associates](mailto:carol@ala.associates) - [juliette@ala.associates](mailto:juliette@ala.associates)  
UK/US: +44 1273 952 481

---